Discover how top pharma are building their upcoming clinical trials…
According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030.
With pharma having discovered the pitfalls of individual, siloed solutions, many are building a new clinical trial technology foundation that can better scale according to their needs.
Discover from 4 top minds in life sciences what the next model of clinical conduct looks like, what it does for sites and patients, and why foundational platforms are critical for the future of digital clinical conduct.
Get the latest insights from Gilead Sciences, Veeva, Syneos Health & Medable now!
